About Viyash
Viyash is a company based in Hyderabad (India) founded in 2019 by Srihari Raju Kalidindi and Haribabu Bodepudi. Viyash has raised $120.02 million across 2 funding rounds from investors including The Carlyle Group, Veeramachaneni Sirisha and Bodepudi Vls Kumari. Viyash has completed 1 acquisition, including Symed. Viyash offers products and services including Finished Dosages, APIs, and Intermediates. Viyash operates in a competitive market with competitors including Inventys, Blue Jet Healthcare, Ami organics, Aparna Pharmaceuticals and DUDE CHEM, among others.
- Headquarter Hyderabad, India
- Founders Srihari Raju Kalidindi, Haribabu Bodepudi
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Viyash Life Sciences Private Limited
- Date of Incorporation 21 Feb, 2019
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$159.42 M (USD)11.63as on Mar 31, 2024
-
Net Profit
-$994.63 K (USD)94.99as on Mar 31, 2024
-
EBITDA
$16.96 M (USD)1688.45as on Mar 31, 2024
-
Total Equity Funding
$120.02 M (USD)
in 2 rounds
-
Latest Funding Round
$111.96 M (USD), Angel Round
Jul 05, 2021
-
Investors
The Carlyle Group
& 38 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Viyash
Viyash offers a comprehensive portfolio of products and services, including Finished Dosages, APIs, and Intermediates.
Manufactured formulations for animal health and treatment applications
Essential components for pharmaceutical drug production processes
Precursors used in synthesizing active pharmaceutical ingredients
People of Viyash
Unlock access to complete
Funding Insights of Viyash
Viyash has successfully raised a total of $120.02M across 2 strategic funding rounds. The most recent funding activity was a Angel Round of $111.96 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Viyash
Viyash has secured backing from 39 investors, including angel and venture fund investors. Prominent investors backing the company include The Carlyle Group, Veeramachaneni Sirisha and Bodepudi Vls Kumari.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
VS
Veeramachaneni Sirisha |
-
|
Locked | Locked | Locked |
|
BV
Bodepudi Vls Kumari |
-
|
Locked | Locked | Locked |
Investor details for Viyash
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viyash
Viyash has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Symed.
Investment portfolio details for Viyash
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
APIs are manufactured and drug development services are provided.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Viyash
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Viyash
Detailed financials for Viyash
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viyash Comparisons
Peer comparison for Viyash
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Viyash
Viyash operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inventys, Blue Jet Healthcare, Ami organics, Aparna Pharmaceuticals and DUDE CHEM, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Actives, advanced intermediates, and specialty chemicals are custom manufactured.
|
|
| Locked | Locked | Locked |
CDMO focused on manufacturing, supplier, and development of intermediates & APIs
|
|
| Locked | Locked | Locked |
Advanced API intermediates are manufactured for pharmaceutical use.
|
|
| Locked | Locked | Locked |
API intermediates are manufactured by Aparna Pharmaceuticals as a CDMO.
|
|
| Locked | Locked | Locked |
CDMO focused on manufacturing of APIs and intermediates
|
Detailed competitors of Viyash
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viyash
Complete news archive for Viyash
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viyash
Viyash was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Viyash is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Haribabu Bodepudi is the current CEO of Viyash. They have also founded this company.
Viyash is a funded company, having raised a total of $120.02M across 2 funding rounds to date.
Annual revenue of Viyash is $159.42M as on Mar 31, 2024.
Viyash was established in 2019 in Hyderabad, India, as a contract development and manufacturing organization. Focus is placed on the production of active pharmaceutical ingredients and intermediates within the pharmaceutical sector. Operations are managed from the companys base in India, with leadership provided by co-founders Haribabu Bodepudi as CEO and Srihari Raju Kalidindi as COO. Services encompass development and manufacturing for pharmaceutical needs.
Viyash's top competitors include Inventys, Blue Jet Healthcare and Ami organics.
Viyash offers Finished Dosages, APIs, and Intermediates.
Viyash has made 1 acquisition, including Symed.
Viyash has 39 investors. Key investors include The Carlyle Group, Veeramachaneni Sirisha, Bodepudi Vls Kumari, Kota Krishna Rao, and Haribabu Bodepudi.
The valuation of Viyash is $249.09M as of Jul 2021.